30 closest matches · ranked by relevance
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Gastrointestinal Cancer
Primary: Serious Adverse Events — 0 Participants
Advanced Gastrointestinal Malignancies
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
High Risk Polyposis Syndrome · Distal Colonic Lesions · Colorectal Polyps
Primary: Number of Neoplastic Lesions Detected — 3 Lesions
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Gastrointestinal Stromal Tumors
Primary: Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0. — 0; 14; 21; 6 Participants
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Gastrointestinal Stromal Tumors
Primary: Progression-Free Survival (PFS) — 6.44 months
Gastrointestinal Stromal Tumors
Primary: Percent of Patients Achieving Stable Disease (SD) — 48.8 % participants
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Primary: Progression-free Survival (PFS) — 46.4 weeks
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma
Primary: Functional Assessment of Cancer Therapy (Quality of Life Measure) — 81.10; 77.70 units on a scale
Gastrointestinal Stromal Tumor
Primary: Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease…
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Gastrointestinal Stromal Tumor (GIST)
Primary: Recurrence-free Survival up to 60 Months — 9; 7; 2; 82 participants with an event
Gastrointestinal Stromal Tumor
Primary: Progression-free Survival (PFS) — 3.9 months
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
GIST
Primary: Clinical Benefit Rate (CBR) in Cohort A — 35.7 percentage (%) of participants
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Advanced Gastrointestinal Stromal Tumors
Primary: Number of Participants With Non Progression at 4 Months — 3 Participants
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival — 147; 28 Days — p=<0.000001
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
Constipation, Impaction, and Bowel Obstruction · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Days Alive and Outside of the Hospital — 42.6; 43.9; 54.8; 52.7 days — p=0.50